Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of FDL169 and FDL176 in Healthy Subjects
NCT03516331Phase 1Completed
- Sponsor
- Flatley Discovery Lab
- Start
- Mar 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FDL176 and FDL169 in cystic fibrosis (CF) (2 arms), sponsored by Flatley Discovery Lab. Primary endpoint: Maximum Plasma Concentration at 72 days. Started Mar 2018; status: completed.
02
Drugs
FDL176FDL169
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03516331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516331.